Medtronic (NYSE:MDT – Get Free Report) will likely be releasing its Q2 2027 results before the market opens on Tuesday, November 24th. Analysts expect Medtronic to announce earnings of $1.33 per share and revenue of $9.48 billion for the quarter. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Parties are encouraged to explore the company’s upcoming Q2 2027 earnings summary page for the latest details on the call scheduled for Tuesday, November 24, 2026 at 7:30 AM ET.
Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The firm had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. During the same period in the prior year, the company posted $1.26 earnings per share. The business’s revenue for the quarter was up 13.7% on a year-over-year basis. On average, analysts expect Medtronic to post $5.98 EPS for the current fiscal year and $6.35 EPS for the next fiscal year.
Medtronic Stock Down 0.7%
NYSE MDT opened at $99.88 on Friday. The business has a fifty day moving average price of $94.62 and a two-hundred day moving average price of $88.45. The stock has a market capitalization of $127.75 billion, a PE ratio of 24.60, a PEG ratio of 2.34 and a beta of 0.56. Medtronic has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54.
Insiders Place Their Bets
In other Medtronic news, CEO Geoffrey Martha sold 50,000 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the sale, the chief executive officer directly owned 277,866 shares in the company, valued at approximately $26,397,270. This trade represents a 15.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Marinaro sold 10,420 shares of Medtronic stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $96.00, for a total value of $1,000,320.00. Following the completion of the sale, the executive vice president owned 105,916 shares of the company’s stock, valued at $10,167,936. The trade was a 8.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 61,903 shares of company stock worth $5,889,203. 0.27% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on MDT. Needham & Company LLC reissued a “buy” rating on shares of Medtronic in a research note on Thursday, September 17th. Barclays raised shares of Medtronic to a “hold” rating in a research report on Wednesday, October 7th. BTIG Research boosted their target price on shares of Medtronic from $99.00 to $109.00 and gave the company a “buy” rating in a report on Thursday. UBS Group reissued a “cautious” rating on shares of Medtronic in a report on Wednesday, October 14th. Finally, Weiss Ratings upgraded shares of Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, October 19th. Eighteen research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $104.17.
Get Our Latest Research Report on MDT
About Medtronic
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
Further Reading
- Five stocks we like better than Medtronic
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
